Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT00372853

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00372853. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675,206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.

Study identification

NCT ID: NCT00372853
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: AstraZeneca; Industry
Enrollment: 28 participants

Conditions and interventions

Conditions

Carcinoma, Renal Cell

Interventions

CP-675,206 Drug
SU011248 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2006 (Type not available)
Primary completion: May 2010 (Actual)
Completion: May 2010 (Actual)
Last update posted: Jun 6, 2012

2006 – 2010

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Research Site	Scottsdale	Arizona	85258	—
Research Site	New Brunswick	New Jersey	08903	—
Research Site	Cleveland	Ohio	44195	—
Research Site	Greenville	South Carolina	29605	—
Research Site	Memphis	Tennessee	38120	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00372853, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 6, 2012 · Synced Nov 15, 2026